Sanofi (EPA: SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 126.42B |
| Revenue (ttm) | 47.08B |
| Net Income (ttm) | 4.22B |
| Shares Out | 1.25B |
| EPS (ttm) | 3.36 |
| PE Ratio | 30.01 |
| Forward PE | 12.36 |
| Dividend | 3.76 (3.70%) |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 1,472,066 |
| Open | 100.76 |
| Previous Close | 101.72 |
| Day's Range | 98.64 - 101.00 |
| 52-Week Range | 80.60 - 106.14 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 25, 2024 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial StatementsNews
Sanofi consumer health unit bidders revising offers over talc powder concerns - report
Sanofi's potential sale of its consumer unit faces uncertainty as bidders rethink offers amid talcum powder product liability concerns. Read more here.
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with kn...
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE: GSK), Sanofi SA (NASDAQ: SNY) and Australian firm CSL Limited (OTC: CSLLY) to more than double the U.S. supply o...
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract
GSK (GSK), Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an ext...
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ: SNY) for $825 million as an upfront payment and additional commer...
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
Sanofi inks $1B deal to sell autoimmune disorder therapy
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infecti...
Recordati buys rights to rare immune disorder drug from Sanofi for $825mln
The deal includes additional commercial milestone payments of up to $250mln and will be completed by year-end, subject to regulatory approval
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry compar...
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business.
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and Regeneron/Sanofi Dupixent taking their place. Read more here.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1258313730-0e4b70681116421db9e5998c346ca9a2.jpg)
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic ob...
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary d...
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Sanofi, Regeneron get additional Chinese approval for Dupixent
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Fr...
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD a...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two l...